Disclosures for "Update on Phase 2 of KYSA-6, an Open-label, Single-arm, Multicenter Phase 2/3 Study of Miv-cel (Mivocabtagene Autoleucel; KYV-101), a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy in Generalized Myasthenia Gravis (gMG)"
-
Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols, . Dr. Dalakas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dysimmune Diseases Foundation. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KYVERNA. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurology (TAND). Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink.
-
Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for argenx. Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB/Ra Pharma. Dr. Muppidi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizont Pharma. Dr. Muppidi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for J & J pharma. Dr. Muppidi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dianthus Pharma. Dr. Muppidi has received publishing royalties from a publication relating to health care.
-
Dr. Hunter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hunter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen.
-
Prof. Hoffmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Prof. Hoffmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Prof. Hoffmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Prof. Hoffmann has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Prof. Hoffmann has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. Prof. Hoffmann has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Prof. Hoffmann has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Grifols. The institution of Prof. Hoffmann has received research support from Janssen. The institution of Prof. Hoffmann has received research support from Argenx.
-
Tobias Hegelmaier has nothing to disclose.
-
The institution of Prof. Motte has received research support from Ruhr-Univerity Bochum.
-
Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen . Dr. Gold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer Vital. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharamaceuticals. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SAGE Publishers. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Novartis. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Biogen. The institution of Dr. Gold has received research support from Novartis. The institution of Dr. Gold has received research support from Biogen.
-
Mrs. Schubert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx, Alexion, Johnson&Johnson. Mrs. Schubert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion, Argenx.
-
Dr. Hunter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kite Pharma. Dr. Hunter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Hunter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Hunter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Johnson & Johnson. Dr. Hunter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Caribou Biosciences. Dr. Hunter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for In8 Bio. Dr. Hunter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Hunter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Hunter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Hunter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseida Therapeutics . Dr. Hunter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kite Pharma. Dr. Hunter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie/Genmab. Dr. Hunter has stock in Actinium Pharmaseuticals. The institution of Dr. Hunter has received research support from Johnson & Johnson.
-
Dr. Hütter-Krönke has nothing to disclose.
-
Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sobi. Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pierre Fabre. Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Gilead. Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mikrogen. Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson&Johnson. Dr. Schultze-Florey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda.
-
Roland Schroers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KYVERNA.
-
Prof. Ayuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kite/Giliead. Prof. Ayuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Prof. Ayuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Prof. Ayuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Miltenyi Biomedicine. Prof. Ayuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Prof. Ayuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Therakos. The institution of Prof. Ayuk has received research support from Therakos. The institution of Prof. Ayuk has received research support from Neovii.
-
Dr. Chou has received personal compensation for serving as an employee of Kyverna Therapeutics. Dr. Chou has received intellectual property interests from a discovery or technology relating to health care.
-
Xue Han has received personal compensation for serving as an employee of Kyverna. The institution of Xue Han has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Kyverna.
-
Dr. Sun has received personal compensation for serving as an employee of Kyverna Therapeutics, Inc.
-
Dr. Sengupta has received personal compensation for serving as an employee of Kyverna Therapeutics. Dr. Sengupta has or had stock in Kyverna Therapeutics. An immediate family member of Dr. Sengupta has or had stock in Kyverna Therapeutics.
-
Dr. Bryant has received personal compensation for serving as an employee of Kyverna Therapeutics. Dr. Bryant has or had stock in Kyverna Therapeutics.
-
Dr. Sun has received personal compensation for serving as an employee of Denali Therapeutics. Dr. Sun has stock in Denali Therapeutics.
-
Dr. Grayson has received personal compensation for serving as an employee of Kyverna Therapeutics.
-
Dr. Gehchan has received personal compensation for serving as an employee of Kyverna Tx. Dr. Gehchan has received personal compensation for serving as an employee of Eli Lilly. Dr. Gehchan has stock in Eli Lilly.
-
Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. The institution of Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Galapagos. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyverna. Dr. Haghikia has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neuraxpharm. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving as a speaker with Biogen. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving as a speaker with Sanofi. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving as a speaker with Novartis. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving as a speaker with Merck Serono. Dr. Haghikia has received personal compensation in the range of $500-$4,999 for serving as a speaker with Celgene.